Mirae Asset Global Investments
CTNM

Mirae Asset Global Investments’s Contineum Therapeutics CTNM Stock Holding History

Mirae Asset Global Investments’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24K Sell
1,464
-124
-8% -$1.63K ﹤0.01% 1464
2026
Q1 		$20.7K Buy
1,588
+466
+42% +$6.25K ﹤0.01% 1430
2025
Q4 		$12.8K Buy
+1,122
New +$12.8K ﹤0.01% 1590

Other funds holding CTNM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mirae Asset Global Investments's CTNM Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Contineum Therapeutics (CTNM) stake by 7.8% in Q2 2026, selling an estimated $1.63K and leaving 1,464 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #1464.

Mirae Asset Global Investments first reported a position in CTNM in Q4 2025 and has held it in 3 quarters since. 21 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Mirae Asset Global Investments held 1,464 shares of Contineum Therapeutics worth $24K as of Q2 2026.
  • Mirae Asset Global Investments sold 124 Contineum Therapeutics shares in Q2 2026, an estimated $1.63K.
  • Contineum Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1464 holding.
  • Mirae Asset Global Investments first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 21 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.